PharmaTelevision - QRx Pharma Ltd: Janette Dixon. Addressing the need for a better safer opioid product with MoxDuo-IR

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: QRx Pharma Ltd: Janette Dixon. Addressing the need for a better safer opioid product with MoxDuo-IR

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Janette Dixon, Vice President of Global Business Development at QRx Pharma Ltd.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Lead product MoxDuo:Technology and advantages

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at AusBiotech's convention, in Adelaide. On this show I have Janette Dixon, who is a Senior Vice President of a company called QRx which is an Australian company listed company with operations both here in Australia, but also substantially in New Jersey, USA. Welcome.

Janette Dixon:

Thanks very much Fintan, it's great to be here.

Fintan Walton:

So Janette, obviously QRx as I said is an Australian company, could you just tell us what is QRx? What is the focus of its products? How would you describe the company?

Janette Dixon:

Sure, so the Q in QRx comes from Queensland, so yes we are an Australian company and we have developing a technology that came out of the University of Queensland, it's a Dual-Opioid platform a combination of two different opioids together in the same product and we are developing that under the MoxDuo brand, we have several products in development our lead product is the immediate release formulation.

Fintan Walton:

Okay, so what is the advantage of MoxDuo-IR?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Janette Dixon

Senior Vice President

At the time of recording this PTV interview Janette Dixon serves as Senior Vice President, Global Business Development at QRxPharma Ltd and CEO of Venomics Pty Ltd (a QRxPharma Ltd subsidiary). Formerly a medical scientist, Janette has extensive commercial experience at executive and director level in both start-up and corporate organizations in the fields of pharmaceuticals and clinical diagnostics. She has degrees in medical technology, marketing, finance and a Doctorate in Business and Administration wherein her research focused on the strategic management of biotech commercialization. Prior to joining QRxPharma , Janette held the role of Managing Director at Pacific Pharmaceuticals Ltd (now Mylan New Zealand Ltd) and led the restructuring of New Zealand's largest pharmaceutical manufacturing company, outsourcing production of 130 pharmaceutical products into six countries. Janette has spent 12 years living and working in Asia and has broad business development experience in the life sciences sector across Asia Pacific and more recently across the US and Europe. Janette founded and is a Director of Singapore based Synergy Pharmaceuticals Pte Ltd, a clinical stage company developing a drug for the eradication of Helicobacter pylori. She previously founded and successfully sold two diagnostics companies based in Singapore and Malaysia and has negotiated and implemented two joint ventures on behalf of QRxPharma with Chinese pharmaceutical companies.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

QRxPharma Ltd

QRxPharma Ltd (ASX: QRX) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders . On May 25, 2007, QRxPharma completed an underwritten initial public offering under the symbol "QRX" on the Australian Securities Exchange (ASX). QRxPharma 's strategy is to commercialize late-stage development products obtained through sponsored research and in-licensing of clinical-stage compounds. The Company's Dual-Opioid products target moderate to severe pain , a US$12 billion global opioid prescription market. The goal is to provide greater patient tolerability and a broader selection of analgesic options to pain specialists. QRxPharma remains open and committed to finding the best possible business relationships to expand its US and overseas markets, accelerate revenues, and maximize the value of its product portfolio while providing significant financial return to its shareholders. QRxPharma will initially focus its commercialization efforts in North America and seeks strategic partners for Europe and Asia.